A pH-responsive T₁-T₂ dual-modal MRI contrast agent for cancer imaging

Area of Science:

• Biomedical Engineering
• Materials Science
• Diagnostic Imaging

Background:

• Magnetic resonance imaging (MRI) is crucial for diagnosing diseases but suffers from low sensitivity.
• Developing advanced contrast agents is essential to improve MRI's diagnostic capabilities.

Purpose of the Study:

• To synthesize and characterize a novel MRI contrast agent, SPIO@SiO2@MnO2, designed to overcome sensitivity limitations.
• To investigate the pH-responsive signal recovery mechanism of the contrast agent for enhanced disease detection.

Main Methods:

• Synthesis of SPIO@SiO2@MnO2 nanoparticles with a core-shell structure.
• Evaluation of T1 and T2 contrast intensity changes under varying pH conditions.
• Application of a "dual-contrast enhanced subtraction" imaging technique.
• In vivo testing for tracing liver metastases and monitoring inflammation.

Main Results:

• The SPIO@SiO2@MnO2 agent exhibits pH-dependent T1 and T2 signal changes, with signal recovery in acidic environments.
• The silicon dioxide layer allows precise regulation of contrast quenching and activation.
• The "dual-contrast enhanced subtraction" technique achieved a 12.3-fold increase in contrast sensitivity.
• Successful application in detecting 0.5 mm liver metastases and monitoring tissue inflammation.

Conclusions:

• SPIO@SiO2@MnO2 represents a significant advancement in MRI contrast agents, offering enhanced sensitivity and specificity.
• The pH-responsive nature and tunable properties enable precise visualization of small lesions and inflammatory processes.
• This agent holds great potential for early disease diagnosis and therapeutic monitoring.